BOSTON SCIENTIFIC CORP (BSX.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:BSX • US1011371077

65.6 EUR
-0.4 (-0.61%)
Last: Feb 6, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

5

Taking everything into account, BSX scores 5 out of 10 in our fundamental rating. BSX was compared to 63 industry peers in the Health Care Equipment & Supplies industry. BSX has an average financial health and profitability rating. BSX is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • BSX had positive earnings in the past year.
  • In the past year BSX had a positive cash flow from operations.
  • BSX had positive earnings in 4 of the past 5 years.
  • Of the past 5 years BSX 4 years had a positive operating cash flow.
BSX.DE Yearly Net Income VS EBIT VS OCF VS FCFBSX.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

1.2 Ratios

  • With a decent Return On Assets value of 6.54%, BSX is doing good in the industry, outperforming 71.43% of the companies in the same industry.
  • With a decent Return On Equity value of 11.93%, BSX is doing good in the industry, outperforming 69.84% of the companies in the same industry.
  • BSX's Return On Invested Capital of 8.09% is fine compared to the rest of the industry. BSX outperforms 66.67% of its industry peers.
  • BSX had an Average Return On Invested Capital over the past 3 years of 6.59%. This is below the industry average of 9.98%.
  • The 3 year average ROIC (6.59%) for BSX is below the current ROIC(8.09%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.54%
ROE 11.93%
ROIC 8.09%
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.59%
ROIC(5y)5.7%
BSX.DE Yearly ROA, ROE, ROICBSX.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

1.3 Margins

  • Looking at the Profit Margin, with a value of 14.42%, BSX belongs to the top of the industry, outperforming 80.95% of the companies in the same industry.
  • BSX's Profit Margin has declined in the last couple of years.
  • Looking at the Operating Margin, with a value of 19.40%, BSX belongs to the top of the industry, outperforming 82.54% of the companies in the same industry.
  • BSX's Operating Margin has been stable in the last couple of years.
  • Looking at the Gross Margin, with a value of 68.57%, BSX is in the better half of the industry, outperforming 77.78% of the companies in the same industry.
  • In the last couple of years the Gross Margin of BSX has remained more or less at the same level.
Industry RankSector Rank
OM 19.4%
PM (TTM) 14.42%
GM 68.57%
OM growth 3Y0.91%
OM growth 5Y1.48%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.15%
GM growth 5Y-0.56%
BSX.DE Yearly Profit, Operating, Gross MarginsBSX.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BSX is destroying value.
  • There is no outstanding debt for BSX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BSX.DE Yearly Shares OutstandingBSX.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B
BSX.DE Yearly Total Debt VS Total AssetsBSX.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

  • BSX has an Altman-Z score of 4.54. This indicates that BSX is financially healthy and has little risk of bankruptcy at the moment.
  • BSX has a better Altman-Z score (4.54) than 79.37% of its industry peers.
  • The Debt to FCF ratio of BSX is 3.03, which is a good value as it means it would take BSX, 3.03 years of fcf income to pay off all of its debts.
  • The Debt to FCF ratio of BSX (3.03) is better than 71.43% of its industry peers.
  • A Debt/Equity ratio of 0.48 indicates that BSX is not too dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.48, BSX is in line with its industry, outperforming 47.62% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 3.03
Altman-Z 4.54
ROIC/WACC0.85
WACC9.48%
BSX.DE Yearly LT Debt VS Equity VS FCFBSX.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B 20B

2.3 Liquidity

  • A Current Ratio of 1.51 indicates that BSX should not have too much problems paying its short term obligations.
  • BSX has a Current ratio of 1.51. This is comparable to the rest of the industry: BSX outperforms 44.44% of its industry peers.
  • A Quick Ratio of 0.96 indicates that BSX may have some problems paying its short term obligations.
  • BSX has a Quick ratio of 0.96. This is in the lower half of the industry: BSX underperforms 61.90% of its industry peers.
Industry RankSector Rank
Current Ratio 1.51
Quick Ratio 0.96
BSX.DE Yearly Current Assets VS Current LiabilitesBSX.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 21.51% over the past year.
  • BSX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 26.01% yearly.
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%15.9%

3.2 Future

  • Based on estimates for the next years, BSX will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.63% on average per year.
  • BSX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.66% yearly.
EPS Next Y14.83%
EPS Next 2Y14.13%
EPS Next 3Y13.68%
EPS Next 5Y13.63%
Revenue Next Year11.42%
Revenue Next 2Y11.15%
Revenue Next 3Y10.54%
Revenue Next 5Y10.66%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BSX.DE Yearly Revenue VS EstimatesBSX.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 10B 20B 30B
BSX.DE Yearly EPS VS EstimatesBSX.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 25.33 indicates a quite expensive valuation of BSX.
  • 66.67% of the companies in the same industry are more expensive than BSX, based on the Price/Earnings ratio.
  • BSX's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.93.
  • With a Price/Forward Earnings ratio of 22.09, BSX is valued on the expensive side.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of BSX is on the same level as its industry peers.
  • When comparing the Price/Forward Earnings ratio of BSX to the average of the S&P500 Index (27.77), we can say BSX is valued slightly cheaper.
Industry RankSector Rank
PE 25.33
Fwd PE 22.09
BSX.DE Price Earnings VS Forward Price EarningsBSX.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • BSX's Enterprise Value to EBITDA ratio is a bit more expensive when compared to the industry. BSX is more expensive than 61.90% of the companies in the same industry.
  • BSX's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. BSX is cheaper than 60.32% of the companies in the same industry.
Industry RankSector Rank
P/FCF 30
EV/EBITDA 24.49
BSX.DE Per share dataBSX.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • BSX has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as BSX's earnings are expected to grow with 13.68% in the coming years.
PEG (NY)1.71
PEG (5Y)0.97
EPS Next 2Y14.13%
EPS Next 3Y13.68%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for BSX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BOSTON SCIENTIFIC CORP

FRA:BSX (2/6/2026, 7:00:00 PM)

65.6

-0.4 (-0.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-04
Earnings (Next)04-21
Inst Owners94.07%
Inst Owner ChangeN/A
Ins Owners0.15%
Ins Owner ChangeN/A
Market Cap97.25B
Revenue(TTM)N/A
Net Income(TTM)2.79B
Analysts85.5
Price Target107.92 (64.51%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.27%
Min EPS beat(2)2.49%
Max EPS beat(2)4.06%
EPS beat(4)4
Avg EPS beat(4)5.68%
Min EPS beat(4)2.49%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)6.15%
EPS beat(12)12
Avg EPS beat(12)5.77%
EPS beat(16)15
Avg EPS beat(16)4.37%
Revenue beat(2)2
Avg Revenue beat(2)1.69%
Min Revenue beat(2)0.96%
Max Revenue beat(2)2.43%
Revenue beat(4)4
Avg Revenue beat(4)1.6%
Min Revenue beat(4)0.96%
Max Revenue beat(4)2.43%
Revenue beat(8)8
Avg Revenue beat(8)2.16%
Revenue beat(12)11
Avg Revenue beat(12)2.08%
Revenue beat(16)13
Avg Revenue beat(16)1.61%
PT rev (1m)-1.07%
PT rev (3m)-2.12%
EPS NQ rev (1m)-0.01%
EPS NQ rev (3m)-0.01%
EPS NY rev (1m)0%
EPS NY rev (3m)0.03%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)0.04%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)0.01%
Valuation
Industry RankSector Rank
PE 25.33
Fwd PE 22.09
P/S 5.93
P/FCF 30
P/OCF 24.8
P/B 4.9
P/tB N/A
EV/EBITDA 24.49
EPS(TTM)2.59
EY3.95%
EPS(NY)2.97
Fwd EY4.53%
FCF(TTM)2.19
FCFY3.33%
OCF(TTM)2.65
OCFY4.03%
SpS11.07
BVpS13.38
TBVpS-1.13
PEG (NY)1.71
PEG (5Y)0.97
Graham Number27.92
Profitability
Industry RankSector Rank
ROA 6.54%
ROE 11.93%
ROCE 10.04%
ROIC 8.09%
ROICexc 8.38%
ROICexgc 28.19%
OM 19.4%
PM (TTM) 14.42%
GM 68.57%
FCFM 19.76%
ROA(3y)3.72%
ROA(5y)2.77%
ROE(3y)6.77%
ROE(5y)5.1%
ROIC(3y)6.59%
ROIC(5y)5.7%
ROICexc(3y)6.75%
ROICexc(5y)5.93%
ROICexgc(3y)22.84%
ROICexgc(5y)19.53%
ROCE(3y)8.18%
ROCE(5y)7.08%
ROICexgc growth 3Y9.18%
ROICexgc growth 5Y7.17%
ROICexc growth 3Y4.96%
ROICexc growth 5Y5.6%
OM growth 3Y0.91%
OM growth 5Y1.48%
PM growth 3Y10.12%
PM growth 5Y-24.05%
GM growth 3Y-0.15%
GM growth 5Y-0.56%
F-Score6
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 0.48
Debt/FCF 3.03
Debt/EBITDA 2.18
Cap/Depr 59.36%
Cap/Sales 4.14%
Interest Coverage 250
Cash Conversion 90.6%
Profit Quality 136.98%
Current Ratio 1.51
Quick Ratio 0.96
Altman-Z 4.54
F-Score6
WACC9.48%
ROIC/WACC0.85
Cap/Depr(3y)57.82%
Cap/Depr(5y)54.13%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.85%
Profit Quality(3y)134.31%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
EPS Next Y14.83%
EPS Next 2Y14.13%
EPS Next 3Y13.68%
EPS Next 5Y13.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%15.9%
Revenue Next Year11.42%
Revenue Next 2Y11.15%
Revenue Next 3Y10.54%
Revenue Next 5Y10.66%
EBIT growth 1Y30.66%
EBIT growth 3Y13.12%
EBIT growth 5Y10.92%
EBIT Next Year37.52%
EBIT Next 3Y20.65%
EBIT Next 5Y17.42%
FCF growth 1Y125.15%
FCF growth 3Y26.15%
FCF growth 5Y16.61%
OCF growth 1Y96.47%
OCF growth 3Y22.44%
OCF growth 5Y13.34%

BOSTON SCIENTIFIC CORP / BSX.DE FAQ

What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (BSX.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to BSX.DE.


What is the valuation status for BSX stock?

ChartMill assigns a valuation rating of 3 / 10 to BOSTON SCIENTIFIC CORP (BSX.DE). This can be considered as Overvalued.


How profitable is BOSTON SCIENTIFIC CORP (BSX.DE) stock?

BOSTON SCIENTIFIC CORP (BSX.DE) has a profitability rating of 6 / 10.


What is the valuation of BOSTON SCIENTIFIC CORP based on its PE and PB ratios?

The Price/Earnings (PE) ratio for BOSTON SCIENTIFIC CORP (BSX.DE) is 25.33 and the Price/Book (PB) ratio is 4.9.


Can you provide the expected EPS growth for BSX stock?

The Earnings per Share (EPS) of BOSTON SCIENTIFIC CORP (BSX.DE) is expected to grow by 14.83% in the next year.